In Depth 11 Oct 2023 Project NextGen: The U.S. government’s $5 billion initiative to stay one step ahead of COVID-19 When SARS-CoV-2 spread out of Wuhan, China, to the rest of the world, it became only the fifth pandemic to be documented since the 1918 flu pandemic. As the entire world went into lockdown, waiting in anticipation for a miracle treatment, the scientific community accomplished what had never been accomplished before, developing first-of-their-kind vaccines against […] October 11, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Oct 2023 Will the U.S. Cancer Moonshot program land its target to halve cancer death rates? It was predicted that more than 600,000 people would die from cancer last year in the U.S., according to the American Cancer Society. But what if those figures could be halved over the next couple of decades? Although no small feat, that’s precisely what the Cancer Moonshot program aims to do. The White House initiative, […] October 6, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 29 Sep 2023Beyond Biotech podcast 65 – Disease X and pandemic preparedness Disease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 vaccine development […] September 29, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 4 Aug 2023Beyond Biotech podcast 57: Group B Strep To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due […] August 4, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 New CHAIN Biotech funding to aid CADD therapeutic platform CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Recbio shingles vaccine clinical trial approved Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 11 Jul 2023 Unlocking the power of mRNA technology By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […] July 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 10 Jul 2023 Five innovations to take RNA vaccines to the next level By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […] July 10, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2023 GSK gonorrhea vaccine fast tracked The US Food and Drug Administration (FDA) has granted a Fast Track designation for GSK plc’s Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of […] June 27, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2023 Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta (Abeta) has provided hope for patients, a significant boost to the sector but also a strong validation of the “amyloid hypothesis”: removing Abeta plaques is a valid therapeutic strategy for […] June 13, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2023 Rabies vaccine gets phase 3 trial approval YS Biopharma Co. Ltd.’s PIKA rabies vaccine has been granted phase 3 clinical trial approval from the Food and Drug Administration of the Philippines. The phase 3 clinical trial, which is planned to commence later in 2023, is a multi-center, multi-country study designed to evaluate the safety and immunogenicity of the vaccine. The study will […] June 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Exothera partners with Quantoom and launches DNA business unit Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email